SCHEMBL244232

SCHEMBL244232

O=S(=O)(O)CCCN(CCCS(=O)(=O)O)c1ccc(C(c2ccc(N(CCCS(=O)(=O)O)CCCS(=O)(=O)O)cc2)c2ccc(N(CCCS(=O)(=O)O)CCCS(=O)(=O)O)cc2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 9/20 0.35
KMT2A Q03164 2/20 0.34
LMNA P02545 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
TP53 P04637 1/20 0.34
ATM Q13315 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ALDH1A1 P00352 3/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
MEN1 O00255 1/20 0.33
HSP90AA1 P07900 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
CYP2C19 P33261 1/20 0.33
TSHR P16473 3/20 0.33
APP P05067 1/20 0.32
EGFR P00533 1/20 0.32
ERBB2 P04626 1/20 0.32
GRK6 P43250 1/20 0.32
MAPT P10636 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3452805 0.98 CNR2 (0.35) CNR2KMT2ALMNASMN1; SMN2TP53
SCHEMBL4936634 0.84 KMT2A (0.39) CNR2KMT2ALMNASMN1; SMN2TP53
SCHEMBL13086215 0.81 CNR2 (0.41) CNR2KMT2AALDH1A1L3MBTL1MEN1
SCHEMBL4443205 0.81 CYP2D6 (0.44) CNR2KMT2ALMNATP53ALDH1A1
SCHEMBL9347243 0.80 LTA4H (0.38) CNR2KMT2ALMNASMN1; SMN2NPSR1
SCHEMBL25081942 0.77 MAPK1 (0.41) KMT2ASMN1; SMN2ALDH1A1L3MBTL1MEN1
SCHEMBL16749608 0.77 CYP19A1 (0.43)
SCHEMBL25082006 0.77 MAPK1 (0.41) KMT2ASMN1; SMN2ALDH1A1L3MBTL1MEN1
SCHEMBL4434764 0.76 MAPT (0.45) KMT2AATMALDH1A1L3MBTL1MEN1
SCHEMBL9644373 0.75 ALDH1A1 (0.41) CNR2KMT2ALMNASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3461908-B1 MEASUREMENT OF GLYCOPROTEIN ARKRAY INC (JP) 2023-08-30 EP claimed
US-11313863-B2 Measurement of glycoprotein ARKRAY, INC. (JP) 2022-04-26 US claimed
US-11262365-B2 Kit for hemoglobin A1C quantitative analysis I-SENS, INC. (KR) 2022-03-01 US claimed
EP-3527669-B1 KIT FOR HEMOGLOBIN A1C QUANTITATIVE ANALYSIS I SENS INC (KR) 2020-04-29 EP claimed
EP-3527669-A1 KIT FOR HEMOGLOBIN A1C QUANTITATIVE ANALYSIS i-Sens, Inc. (KR) 2019-08-21 EP claimed
US-20190242910-A1 KIT FOR HEMOGLOBIN A1C QUANTITATIVE ANALYSIS I-SENS, INC. (KR) 2019-08-08 US claimed
US-20190137509-A1 Measurement of Glycoprotein ARKRAY, INC. (JP) 2019-05-09 US claimed
EP-3461908-A1 MEASUREMENT OF GLYCOPROTEIN ARKRAY, Inc. (JP) 2019-04-03 EP claimed
US-8557591-B2 Methods for assaying percentage of glycated hemoglobin GENERAL ATOMICS (US) 2013-10-15 US claimed
EP-1515144-B2 METHOD OF ASSAY WITH SULFONIC ACID COMPOUND AND NITRO COMPOUND ARKRAY INC (JP) 2013-04-24 EP claimed
EP-1515144-B1 METHOD OF ASSAY WITH SULFONIC ACID COMPOUND AND NITRO COMPOUND ARKRAY INC (JP) 2009-10-14 EP claimed
EP-2044444-A1 METHODS FOR ASSAYING PERCENTAGE OF GLYCATED HEMOGLOBIN GENERAL ATOMICS (US) 2009-04-08 EP claimed
US-20080299597-A1 METHODS FOR ASSAYING PERCENTAGE OF GLYCATED HEMOGLOBIN DIAZYME LABORATORIES, INC. 2008-12-04 US claimed
US-20080096230-A1 Methods for assaying percentage of glycated hemoglobin DIAZYME LABORATORIES, INC. 2008-04-24 US claimed
US-7354732-B2 Method of assay with sulfonic acid compound and nitro compound ARKRAY, INC. (JP) 2008-04-08 US claimed
WO-2008013874-A1 METHODS FOR ASSAYING PERCENTAGE OF GLYCATED HEMOGLOBIN GENERAL ATOMICS (US) 2008-01-31 WO claimed
US-20070026523-A1 Method for stabilizing leuco dye DAIICHI PURE CHEMICALS CO., LTD. (JP) 2007-02-01 US claimed
EP-1726955-A1 METHOD OF STABILIZING OXIDIZABLE COLOR-ASSUMING REAGENT DAIICHI PURE CHEMICALS CO., LTD. (JP) 2006-11-29 EP claimed
US-20050221415-A1 Method of assay with sulfonic acid compound and nitro compound ARKRAY, INC. (JP) 2005-10-06 US claimed
EP-1515144-A1 METHOD OF ASSAY WITH SULFONIC ACID COMPOUND AND NITRO COMPOUND ARKRAY, Inc. (JP) 2005-03-16 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190137509-A1 Measurement of Glycoprotein CD4, SIGLEC7, FUT7 CNR2 4122/4885KMT2A 4613/4885LMNA 1845/4885
US-11313863-B2 Measurement of glycoprotein HBG1, HBG2, HBB CNR2 1696/4885KMT2A 3253/4885LMNA 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.